Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02967679
Recruitment Status : Completed
First Posted : November 18, 2016
Results First Posted : November 2, 2020
Last Update Posted : November 2, 2020
Sponsor:
Information provided by (Responsible Party):
MedDay Pharmaceuticals SA

Brief Summary:
The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.

Condition or disease Intervention/treatment Phase
Chronic Inflammatory Demyelinating Polyneuropathy Peripheral Neuropathy Charcot-Marie-Tooth Disease Charcot-Marie-Tooth Disease Type 1A Charcot-Marie-Tooth Disease, Type 1B Anti-MAG Neuropathy Drug: MD1003 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Actual Study Start Date : December 5, 2016
Actual Primary Completion Date : March 18, 2019
Actual Study Completion Date : March 18, 2019


Arm Intervention/treatment
Experimental: MD1003
MD1003 100mg capsules, 1 capsule tid for 48 weeks
Drug: MD1003
Other Name: High Dose Biotin




Primary Outcome Measures :
  1. Motor Nerve Conduction Velocity (m/Sec) [ Time Frame: 48 weeks ]
    Absolute change from baseline at Week 48.

  2. Distal Latency (Msec) [ Time Frame: 48 weeks ]
    Absolute change from baseline at Week 48.

  3. F Wave Latency (Msec) [ Time Frame: 48 weeks ]
    Absolute change from baseline at Week 48.

  4. Length of Motor Nerve Potential [ Time Frame: 48 weeks ]
    Absolute change from baseline at W48.


Secondary Outcome Measures :
  1. ONLS (Overall Neuropathy Limitations Scale) [ Time Frame: 48 weeks ]
    The ONLS focuses on upper and lower limb functions, and consists of a checklist for interviewing patients. It is scored from 0 to 5 on the upper limb section and from 0 to 7 on the lower limb section. A score of 0 indicates no limitations (the ceiling of the scale) and a score of 5 or 7 indicates no purposeful movement. Absolute change from baseline at week 48.

  2. Change From Baseline at Week 48 for Timed 10-meter Walk Test [ Time Frame: 48 weeks ]
    Absolute change from baseline at week 48. The patient is instructed to walk at normal pace for 10 meters. Start and stop of performance time coincides with the toes of the leading foot crossing the 2-m mark and the 8-m mark, respectively. From these data, the speed may be calculated by dividing the middle 6 m by the time (in seconds).

  3. Absolute Change From Baseline at Week 48 for Medical Research Council (MRC) Subscore (Total Muscle) and Total Score [ Time Frame: 48 weeks ]

    MRC score assessed in 19 muscles.

    The muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle.

    The patient's effort is graded on a scale of 0-5:

    Grade 5: Muscle contracts normally against full resistance. Grade 4: Muscle strength is reduced but muscle contraction can still move joint against resistance.

    Grade 3: Muscle strength is further reduced such that the joint can be moved only against gravity with the examiner's resistance completely removed. As an example, the elbow can be moved from full extension to full flexion starting with the arm hanging down at the side.

    Grade 2: Muscle can move only if the resistance of gravity is removed. As an example, the elbow can be fully flexed only if the arm is maintained in a horizontal plane.

    Grade 1: Only a trace or flicker of movement is seen or felt in the muscle or fasciculations are observed in the muscle.

    Grade 0: No movement is observed.


  4. INCAT Sensory Sum Score (ISS) [ Time Frame: 48 weeks ]
    This sensory scale comprises pin prick and vibration sense plus a two point discrimination value in the arms and legs, and ranges from 0 ("normal sensation") to 20 ("most severe sensory deficit"). Absolute change from baseline at week 48.

  5. 6-minute Walk Test [ Time Frame: 48 weeks ]
    The 6MWT is a practical simple test that requires a 30 m (100-ft) hallway. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. Absolute change from baseline at week 48.

  6. Posturography Score [ Time Frame: 48 weeks ]
    Computerized dynamic posturography (CDP) is a non-invasive specialized clinical assessment technique used to quantify the central nervous system adaptive mechanisms (sensory, motor and central) involved in the control of posture and balance, both in normal and abnormal conditions. Absolute change of speed in spontaneous speed condition from baseline at week 48.

  7. Excitability Testing: Supernormality (%) [ Time Frame: 48 weeks ]

    Nerve excitability testing is a non-invasive approach in investigating the pathophysiology of peripheral nerve disorders, which determines the electrical properties of the nerve membrane at the site of stimulation. Absolute change from baseline at week 48.

    After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). During the 10-30 ms following the end of the refractory period, the axon increases its excitability and the nerve fiber is more easily excited (the supernormal period). Depolarization of the node of Ranvier excites the adjacent internodes, which then charge with electric current as capacitors. Supernormality depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.


  8. Strength-duration Time Constant (ms) [ Time Frame: 48 weeks ]

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.

    Strength-duration Time Constant (ms) is a measurement of excitability, defined as the duration of the stimulus that has twice the strength of the rheobase current (see below). The lower the rheobase is, the higher is the Strenght duration time constant. Accordingly, higer values of SDTC are associated with better outcome.


  9. Rheobase (mA) [ Time Frame: 48 weeks ]

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.

    Rheobase is the minimal strength of an electrical stimulus of infinitely long duration that is able to cause excitation. Low values are associated with better outcome (the nerve becomes more excitable).


  10. Refractoriness (%) [ Time Frame: 48 weeks ]

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline to week 48.

    After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.


  11. Minimum Absolute Refractory Period (ms). [ Time Frame: 48 weeks ]

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.

    After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.


  12. Maximum Absolute Refractory Period (ms). [ Time Frame: Week 48 ]

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.

    After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female aged between 20 and 85 years.
  • Patients fulfilling one of the following diagnosis:
  • Five patients with chronic inflammatory demyelinating polyneuropathy on both clinical and neurophysiological grounds.
  • Five patients with proven genetic diagnosis of CMT1a or CMT1b
  • Five patients with anti-MAG polyneuropathy.
  • Electrophysiological parameters worsening for the past 3 years
  • Available EMG record, performed during the past 6 months to assess variability of NCV parameters
  • Signed and dated written informed consent to participate in the study in accordance with local regulations
  • Likely to be able to participate in all scheduled evaluation and complete all required study procedures,
  • In the opinion of the investigator, the patient will be compliant and have a high probability of completing the study.
  • Both male and female subjects who are not either surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or post-menopausal (no spontaneous menstrual periods for at least one year confirmed by a negative hormone panel) must commit to using TWO highly effective method of birth control for the duration of the study and for two months after the treatment termination.

Exclusion Criteria:

  • Any general chronic handicapping disease other than peripheral neuropathy
  • Impossibility to perform the 10 meters walking test
  • Impossibility to assess electrophysiological parameters
  • Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or cancer,
  • Patients with hypersensitivity to MD1003 excipients (lactose)
  • Laboratory tests out of normal range according to the reference laboratory values. Deviations may be accepted if considered by the investigator as not clinically significant with regards to the study continuation,
  • Patients with history or presence of alcohol abuse or drug addiction,
  • Patients likely to be non-compliant to the study procedures or for whom a long-term follow-up seems to be difficult to achieve.
  • Any new medication for neuropathy initiated less than 3 months prior to inclusion. For CIDP patients, relapse in the past 3 months before inclusion.
  • Not easily contactable by the investigator in case of emergency or not capable to call the investigator
  • Subjects without effective contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02967679


Locations
Layout table for location information
France
Hôpital Henri Mondor, Créteil, France
Creteil, France, 94010
Sponsors and Collaborators
MedDay Pharmaceuticals SA
Investigators
Layout table for investigator information
Principal Investigator: Alain CREANGE, MD Hôpital Henri Mondor, Créteil, France
Study Director: Frederic Sedel, MD Medday Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by MedDay Pharmaceuticals SA:
Study Protocol  [PDF] February 10, 2017
Statistical Analysis Plan  [PDF] November 4, 2019

Additional Information:
Layout table for additonal information
Responsible Party: MedDay Pharmaceuticals SA
ClinicalTrials.gov Identifier: NCT02967679    
Other Study ID Numbers: MD1003CT2015-01 SERENDEM
First Posted: November 18, 2016    Key Record Dates
Results First Posted: November 2, 2020
Last Update Posted: November 2, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MedDay Pharmaceuticals SA:
Neuropathy
Demyelinating polyradiculoneuropathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Tooth Diseases
Peripheral Nervous System Diseases
Polyneuropathies
Charcot-Marie-Tooth Disease
Nerve Compression Syndromes
Hereditary Sensory and Motor Neuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Neuromuscular Diseases
Nervous System Diseases
Stomatognathic Diseases
Nervous System Malformations
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Congenital Abnormalities
Genetic Diseases, Inborn
Polyradiculoneuropathy
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Biotin
Vitamin B Complex
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs